Page last updated: 2024-10-26

doxazosin and Coronary Disease

doxazosin has been researched along with Coronary Disease in 62 studies

Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.

Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.

Research Excerpts

ExcerptRelevanceReference
"The Hypertension and Lipid Trial (HALT) was undertaken to assess the efficacy and safety of doxazosin, a selective alpha 1- adrenergic blocker, in patients with hypertension in a clinical practice setting."9.08Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension. ( Levenstein, M; Levy, D; Walmsley, P, 1996)
"The long-term efficacy and safety of once-daily treatment with doxazosin or atenolol were compared in a 5-year study in patients with mild-to-moderate hypertension."9.08A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. ( Daae, LN; Westlie, L, 1998)
" Forty-two patients, ages 42 to 65 years, including 21 men with sustained hypertension and elevated serum cholesterol levels, were included in a trial of monotherapy with doxazosin administered once daily (range, 1 to 16 mg)."9.07Efficacy and safety of doxazosin in the treatment of patients with mild or moderate essential hypertension and elevated levels of cholesterol. ( Taylor, SH, 1991)
"This study was designed to assess the efficacy and tolerance of doxazosin in patients with mild, moderate, or severe essential hypertension in a general practice setting."9.07A multicenter study of doxazosin in the treatment of essential hypertension in France. ( Bonnet, G, 1991)
"A single daily dose of doxazosin taken during a 12-week period produced a significant reduction in blood pressure and left ventricular mass index in patients with mild or moderate hypertension."9.07Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension. ( Fonseca, R; López, B; Lugo de Franco, V; Medina, O; Monsalve, P; Ostojich, K; Pérez Acuña, F; Torres, N; Vera, O, 1991)
"This Latin American study assessed in the general practice setting the efficacy and tolerance of once-daily doxazosin in the treatment of mild or moderate essential hypertension (sitting diastolic blood pressure, 95 to 115 mm Hg)."9.07Doxazosin in the treatment of essential hypertension in general medical practice in Latin America. ( Fonseca, R; Marshall, D; Silva, H, 1991)
"Doxazosin is a selective alpha 1-inhibitor for the reduction of calculated coronary heart disease (CHD) risk in hypertensive patients."9.06Doxazosin versus atenolol: a randomized comparison of calculated coronary heart disease risk reduction. ( Guerrasio, E; Mazzola, C, 1988)
"Doxazosin, a selective alpha 1-inhibitor, was assessed in 34 patients with mild and moderate hypertension."7.67Doxazosin in the treatment of mild and moderate essential hypertension in general medical practice. ( van den Hogen, AL, 1988)
"Although the pathology of essential hypertension is still unclear, studies have shown that doxazosin, a selective alpha 1-inhibitor, is able to effectively control mild-to-moderate hypertension."7.67Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy. ( Rosenthal, J, 1988)
"The impact of treating hypertension on coronary artery disease has been less than anticipated from epidemiologic studies of cardiovascular risk factors."6.67Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group. ( Carruthers, G; Dessain, P; Fodor, G; Newman, C; Palmer, W; Sim, D, 1993)
"Treatment with doxazosin can lower blood pressure, reduce the levels of atherogenic lipids, increase the levels of cardioprotective lipids, reduce hyperinsulinaemia, insulin resistance and glucose intolerance, increase fibrinolysis, inhibit platelet aggregation, attenuate the adverse haemodynamic and haemostatic effects of smoking, and regress cardiac and smooth muscle hypertrophy."5.29Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient. ( Pool, JL, 1994)
"The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was a randomized, double-blind, active, controlled clinical trial conducted to determine whether newer antihypertensive agents, including doxazosin, an alpha-blocker, differ from chlorthalidone, a diuretic, with respect to coronary heart disease (CHD) and other cardiovascular disease (CVD) events in hypertensive patients at high risk of CHD."5.10Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( , 2003)
" The double-blind, active-controlled component of ALLHAT was designed to determine whether the rate of the primary outcome-a composite of fatal coronary heart disease and nonfatal myocardial infarction-differs between diuretic (chlorthalidone) treatment and each of three other classes of antihypertensive drugs: a calcium antagonist (amlodipine), an angiotensin-converting enzyme inhibitor (lisinopril), and an alpha-adrenergic blocker (doxazosin) in high-risk hypertensive persons ages 55 years and older."5.09Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Bettencourt, J; Davis, BR; Ford, CE; Furberg, CD; Geraci, TS; Kimmel, B; Kingry, C; Lusk, C; Nwachuku, C; Parks, H; Piller, LB; Pressel, SL; Simpson, LM; Wright, JT, 2001)
"The Antihypertensive and Lipid-Lowering high-risk hypertensive participants, ages > or = 55 years, designed to determine whether the incidence of fatal and nonfatal coronary heart disease (CHD) and combined cardiovascular events (fatal and nonfatal CHD, revascularization surgery, angina pectoris, congestive heart failure, and stroke) differs between diuretic (chlorthalidone) treatment and three alternative antihypertensive therapies: a calcium channel blocker (amlodipine), an ACE inhibitor (lisinopril), and an alpha-adrenergic blocker (doxazosin)."5.09Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Barzilay, JI; Basile, JN; Ciocon, JO; Davis, BR; Goff, DC; Jones, CL; Randall, OS; Sweeney, ME, 2001)
"The Hypertension and Lipid Trial (HALT) was undertaken to assess the efficacy and safety of doxazosin, a selective alpha 1- adrenergic blocker, in patients with hypertension in a clinical practice setting."5.08Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension. ( Levenstein, M; Levy, D; Walmsley, P, 1996)
"The long-term efficacy and safety of once-daily treatment with doxazosin or atenolol were compared in a 5-year study in patients with mild-to-moderate hypertension."5.08A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. ( Daae, LN; Westlie, L, 1998)
"This Latin American study assessed in the general practice setting the efficacy and tolerance of once-daily doxazosin in the treatment of mild or moderate essential hypertension (sitting diastolic blood pressure, 95 to 115 mm Hg)."5.07Doxazosin in the treatment of essential hypertension in general medical practice in Latin America. ( Fonseca, R; Marshall, D; Silva, H, 1991)
"This study was designed to assess the efficacy and tolerance of doxazosin in patients with mild, moderate, or severe essential hypertension in a general practice setting."5.07A multicenter study of doxazosin in the treatment of essential hypertension in France. ( Bonnet, G, 1991)
"This study was designed to investigate the efficacy and toleration of once-daily doxazosin in the treatment of essential hypertension (sitting diastolic blood pressure 95 to 115 mm Hg) in a general medical practice."5.07Clinical experience with doxazosin in general medical practice in The Netherlands. ( Harmse, DP, 1991)
"A single daily dose of doxazosin taken during a 12-week period produced a significant reduction in blood pressure and left ventricular mass index in patients with mild or moderate hypertension."5.07Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension. ( Fonseca, R; López, B; Lugo de Franco, V; Medina, O; Monsalve, P; Ostojich, K; Pérez Acuña, F; Torres, N; Vera, O, 1991)
" Forty-two patients, ages 42 to 65 years, including 21 men with sustained hypertension and elevated serum cholesterol levels, were included in a trial of monotherapy with doxazosin administered once daily (range, 1 to 16 mg)."5.07Efficacy and safety of doxazosin in the treatment of patients with mild or moderate essential hypertension and elevated levels of cholesterol. ( Taylor, SH, 1991)
"In an open, non-comparative, multicenter trail performed by general practitioners, the efficacy and safety of doxazosin, an inhibitor of postsynaptic alpha 1-adrenoceptors, were studied in 924 patients with mild to moderate hypertension."5.07[Reducing blood pressure and modification of coronary risk factors by therapy with doxazosin]. ( Ganzinger, U; Hitzenberger, G, 1993)
"The antihypertensive efficacy and safety of doxazosin (once daily) and prazosin (twice daily) were compared in patients with mild or moderate essential hypertension (diastolic blood pressure [DBP] 95 to 114 mm Hg) not adequately controlled by diuretics and beta-blockers."5.07A double-blind comparative study of doxazosin and prazosin when administered with beta-blockers or diuretics. ( de Planque, BA, 1991)
"This study investigated the safety and efficacy of doxazosin treatment in a large population of patients (n = 336) with essential hypertension and assessed the effect of doxazosin on the serum lipid profile and the calculated risk of developing coronary heart disease."5.07Clinical experience with doxazosin in general medical practice in New Zealand. ( Maslowski, AH, 1991)
"The efficacy and toleration of doxazosin and atenolol were compared over a 52-week period in a double-blind, multicenter study of 228 patients with mild-to-moderate hypertension."5.06Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients. ( Daae, L; Talseth, T; Vatle, S; Westlie, L, 1988)
"Doxazosin is a selective alpha 1-inhibitor for the reduction of calculated coronary heart disease (CHD) risk in hypertensive patients."5.06Doxazosin versus atenolol: a randomized comparison of calculated coronary heart disease risk reduction. ( Guerrasio, E; Mazzola, C, 1988)
"Doxazosin, a selective alpha 1-inhibitor, was assessed in 34 patients with mild and moderate hypertension."3.67Doxazosin in the treatment of mild and moderate essential hypertension in general medical practice. ( van den Hogen, AL, 1988)
"The antihypertensive efficacy, lipid effects, and safety of doxazosin, a selective alpha 1-inhibitor for the reduction of coronary heart disease (CHD) risk in hypertensive patients, was assessed in a general medical practice setting."3.67Clinical experience with doxazosin in general medical practice. ( Rosenthal, J, 1988)
"Although the pathology of essential hypertension is still unclear, studies have shown that doxazosin, a selective alpha 1-inhibitor, is able to effectively control mild-to-moderate hypertension."3.67Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy. ( Rosenthal, J, 1988)
"The impact of treating hypertension on coronary artery disease has been less than anticipated from epidemiologic studies of cardiovascular risk factors."2.67Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group. ( Carruthers, G; Dessain, P; Fodor, G; Newman, C; Palmer, W; Sim, D, 1993)
"Because coronary heart disease is known to have many causes, primary preventive therapy must logically go beyond the relatively simple goal of lowering blood pressure."2.66Effects of oral antihypertensive agents on blood lipid levels. ( Leren, P, 1986)
" It is readily absorbed, with high bioavailability and a relatively long plasma half-life, neither of which property is influenced by age."2.38Clinical pharmacotherapeutics of doxazosin. ( Taylor, SH, 1989)
"Doxazosin appears to inhibit the development of CHD on two fronts."2.38Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism. ( Pool, JL, 1991)
"Treatment with doxazosin can lower blood pressure, reduce the levels of atherogenic lipids, increase the levels of cardioprotective lipids, reduce hyperinsulinaemia, insulin resistance and glucose intolerance, increase fibrinolysis, inhibit platelet aggregation, attenuate the adverse haemodynamic and haemostatic effects of smoking, and regress cardiac and smooth muscle hypertrophy."1.29Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient. ( Pool, JL, 1994)

Research

Studies (62)

TimeframeStudies, this research(%)All Research%
pre-199020 (32.26)18.7374
1990's28 (45.16)18.2507
2000's13 (20.97)29.6817
2010's1 (1.61)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, BR5
Kostis, JB1
Simpson, LM2
Black, HR1
Cushman, WC1
Einhorn, PT1
Farber, MA1
Ford, CE4
Levy, D2
Massie, BM1
Nawaz, S1
Lynch, AI1
Eckfeldt, JH2
Boerwinkle, E2
Leiendecker-Foster, C2
Arnett, DK2
Wepner, U1
Kuwajima, I1
Miller, MB1
Black, H1
Pool, JL3
Hitzenberger, G1
Ganzinger, U1
Carruthers, G1
Dessain, P1
Fodor, G1
Newman, C1
Palmer, W1
Sim, D1
Walmsley, P1
Levenstein, M1
Daae, LN1
Westlie, L3
Calò, L1
Davis, PA1
Cantaro, S1
Bonfante, L1
Castrignano, R2
Carraro, G1
D'Angelo, A2
Einecke, D1
Miller, JL1
Ball, SG1
Koval, PG1
McDiarmid, T1
Messerli, FH1
Grossman, E1
Schillaci, G1
Verdecchia, P1
Pressel, SL1
Wright, JT1
Geraci, TS1
Kingry, C1
Piller, LB1
Bettencourt, J1
Kimmel, B1
Lusk, C1
Parks, H1
Nwachuku, C1
Furberg, CD1
Barzilay, JI1
Jones, CL1
Basile, JN1
Goff, DC1
Ciocon, JO1
Sweeney, ME1
Randall, OS1
Westby, J4
Birkeland, S3
Lekven, J4
Grong, K4
de Planque, BA1
McInnes, GT1
Passarelli, P1
Galiè, N1
Limonetti, P1
Branzi, A1
Magnani, B1
Hexeberg, E1
Olweus, J1
Myking, OL1
Holme, I1
Fauchald, P1
Rugstad, HE1
Stokke, HP1
Langdon, CG1
Naber, FB1
Talseth, T2
Daae, L2
Wessels, F1
Maslowski, AH1
Silva, H1
Fonseca, R2
Marshall, D1
Bonnet, G1
Harmse, DP1
Monsalve, P1
Vera, O1
Pérez Acuña, F1
Medina, O1
Ostojich, K1
López, B1
Torres, N1
Lugo de Franco, V1
Taylor, SH3
Hernandez Hernandez, R1
Guerrero Pajuelo, JR1
Carvajal, AR1
Armas Padilla, MC1
Armas de Hernandez, MJ1
Barragan, O1
Boada Boada, JJ1
Kvitting, P2
Lenz, ML1
Taylor, AA1
Mohanlal, RW1
Mauve, I1
van der Valk, L1
Bruschke, AV1
van der Laarse, A1
Leren, P1
van den Hogen, AL1
Rosenthal, J2
Bartels, AC1
de Vries, PM1
Oe, LP1
van Bronswÿk, H1
Donker, AJ1
Réveillaud, RJ1
Fillastre, JP1
Zech, P1
Pati, T1
Al Awady, M1
Tronca, R1
Crepaldi, G1
Vatle, S1
Mazzola, C1
Guerrasio, E1
Nechwatal, W1
Berger, J1
Blumrich, W1
Bouzo, H1
Brandl, K1
Braun, S1
Laukaitis, A1
Müller, G1
Ryba, W1
Schreiegg, J1
Lindner, UK1
von Manteuffel, GE1
Stafunsky, M1
Englert, RG1
Mauersberger, H1
Hansson, L1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT00000542]Phase 30 participants Interventional1993-08-31Completed
GenHAT - Genetics of Hypertension Associated Treatments - Ancillary to ALLHAT[NCT00563901]37,939 participants (Actual)Observational2000-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

6 reviews available for doxazosin and Coronary Disease

ArticleYear
[ALLHAT trial--antithesis to the overuse of vasodilating antihypertensive drugs].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 3

    Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypert

2004
The value of alpha-blockers in the management of hypertension: a practical view.
    Journal of human hypertension, 1991, Volume: 5, Issue:4

    Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Coronary Disease; Doxazosin;

1991
Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism.
    American heart journal, 1991, Volume: 121, Issue:1 Pt 2

    Topics: Antihypertensive Agents; Cholesterol; Clinical Trials as Topic; Coronary Disease; Doxazosin; Humans;

1991
Clinical pharmacotherapeutics of doxazosin.
    The American journal of medicine, 1989, Aug-16, Volume: 87, Issue:2A

    Topics: Adrenergic alpha-Antagonists; Coronary Disease; Doxazosin; Hemodynamics; Humans; Hypertension; Prazo

1989
Pharmacotherapeutic stature of doxazosin and its role in coronary risk reduction.
    American heart journal, 1988, Volume: 116, Issue:6 Pt 2

    Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Coronary Disease; Dose-Response Relationship,

1988
Implications of doxazosin therapy on risk of coronary heart disease.
    American heart journal, 1988, Volume: 116, Issue:6 Pt 2

    Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Coronary Disease; Doxazosin; Humans; Lipoprot

1988

Trials

30 trials available for doxazosin and Coronary Disease

ArticleYear
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
    Circulation, 2008, Nov-25, Volume: 118, Issue:22

    Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Antihypertensive Agents; Coronary Disease; Double-Bl

2008
Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study.
    Pharmacogenetics and genomics, 2012, Volume: 22, Issue:5

    Topics: Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Coronary Disease; Doxazosin; Female; Foll

2012
Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Hypertension (Dallas, Tex. : 1979), 2003, Volume: 42, Issue:3

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chlorthalidone; Coronary Dise

2003
Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study.
    The pharmacogenomics journal, 2007, Volume: 7, Issue:2

    Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calmodulin-Binding Proteins; Chlorthalido

2007
[Reducing blood pressure and modification of coronary risk factors by therapy with doxazosin].
    Wiener klinische Wochenschrift, 1993, Volume: 105, Issue:13

    Topics: Adult; Aged; Blood Pressure; Coronary Disease; Dose-Response Relationship, Drug; Doxazosin; Female;

1993
Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group.
    The American journal of cardiology, 1993, Mar-01, Volume: 71, Issue:7

    Topics: Adult; Aged; Atenolol; Cholesterol; Cholesterol, HDL; Coronary Disease; Double-Blind Method; Doxazos

1993
Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension.
    American heart journal, 1996, Volume: 131, Issue:5

    Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Dis

1996
A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk.
    Blood pressure, 1998, Volume: 7, Issue:1

    Topics: Adolescent; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood

1998
Effect of doxazosin in mild to moderate hypertensive patients with insulin-dependent diabetes mellitus.
    Acta diabetologica, 1998, Volume: 35, Issue:2

    Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Coronary Disease; Diabetes Me

1998
[ALLHAT Study: doxazosin arm is discontinued. Alpha blocker is less effective than a diuretic].
    MMW Fortschritte der Medizin, 2000, Mar-30, Volume: 142, Issue:13

    Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chlorthalidone; Coronary Dis

2000
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Controlled clinical trials, 2001, Volume: 22, Issue:1

    Topics: Adverse Drug Reaction Reporting Systems; Antihypertensive Agents; Cause of Death; Coronary Disease;

2001
Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Diabetes care, 2001, Volume: 24, Issue:4

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Ant

2001
A double-blind comparative study of doxazosin and prazosin when administered with beta-blockers or diuretics.
    American heart journal, 1991, Volume: 121, Issue:1 Pt 2

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Coronary Disease; Diuretics; Double-Blind Meth

1991
[Comparative effects of doxazosin and enalapril in patients with arterial hypertension and exercise-induced acute myocardial ischemia].
    Cardiologia (Rome, Italy), 1991, Volume: 36, Issue:10

    Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Coronary Disease; Doxazosin; Enalapril;

1991
Preliminary results of the Norwegian doxazosin postmarketing surveillance study: a twelve-week experience.
    American heart journal, 1991, Volume: 121, Issue:1 Pt 2

    Topics: Antihypertensive Agents; Blood Pressure; Cholesterol; Coronary Disease; Doxazosin; Female; Heart Rat

1991
Doxazosin: a study in a cohort of patients with hypertension in general practice--an interim report.
    American heart journal, 1991, Volume: 121, Issue:1 Pt 2

    Topics: Antihypertensive Agents; Cholesterol; Cohort Studies; Coronary Disease; Doxazosin; England; Family P

1991
An open, noncomparative study of doxazosin in essential hypertension: experience in general practice in The Netherlands.
    American heart journal, 1991, Volume: 121, Issue:1 Pt 2

    Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Female; Humans;

1991
Doxazosin and atenolol as monotherapy in mild and moderate hypertension: a randomized, parallel study with a three-year follow-up.
    American heart journal, 1991, Volume: 121, Issue:1 Pt 2

    Topics: Antihypertensive Agents; Atenolol; Cholesterol; Coronary Disease; Double-Blind Method; Doxazosin; Fe

1991
Double-blind comparison of doxazosin and enalapril in patients with mild or moderate essential hypertension.
    American heart journal, 1991, Volume: 121, Issue:1 Pt 2

    Topics: Antihypertensive Agents; Coronary Disease; Double-Blind Method; Doxazosin; Enalapril; Family Practic

1991
Clinical experience with doxazosin in general medical practice in New Zealand.
    American heart journal, 1991, Volume: 121, Issue:1 Pt 2

    Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Female; Humans;

1991
Doxazosin in the treatment of essential hypertension in general medical practice in Latin America.
    American heart journal, 1991, Volume: 121, Issue:1 Pt 2

    Topics: Antihypertensive Agents; Argentina; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Femal

1991
A multicenter study of doxazosin in the treatment of essential hypertension in France.
    American heart journal, 1991, Volume: 121, Issue:1 Pt 2

    Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Female; France;

1991
Clinical experience with doxazosin in general medical practice in The Netherlands.
    American heart journal, 1991, Volume: 121, Issue:1 Pt 2

    Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Female; Humans;

1991
Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension.
    American heart journal, 1991, Volume: 121, Issue:1 Pt 2

    Topics: Antihypertensive Agents; Cardiomegaly; Cholesterol; Coronary Disease; Doxazosin; Echocardiography; F

1991
Efficacy and safety of doxazosin in the treatment of patients with mild or moderate essential hypertension and elevated levels of cholesterol.
    American heart journal, 1991, Volume: 121, Issue:1 Pt 2

    Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; England; Female; Humans; Hyperten

1991
Evidence of an antiplatelet aggregation action of doxazosin in patients with hypertension: an ex vivo study.
    American heart journal, 1991, Volume: 121, Issue:1 Pt 2

    Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Doxazosin;

1991
Effects of oral antihypertensive agents on blood lipid levels.
    Clinical therapeutics, 1986, Volume: 8, Issue:3

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Cl

1986
Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients.
    American heart journal, 1988, Volume: 116, Issue:6 Pt 2

    Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Coronary D

1988
Doxazosin versus atenolol: a randomized comparison of calculated coronary heart disease risk reduction.
    American heart journal, 1988, Volume: 116, Issue:6 Pt 2

    Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pres

1988
A double-blind comparative study of doxazosin and nitrendipine in patients with mild-to-moderate essential hypertension.
    American heart journal, 1988, Volume: 116, Issue:6 Pt 2

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease

1988

Other Studies

26 other studies available for doxazosin and Coronary Disease

ArticleYear
[Established blood pressure drug wins out in a comparative study. In hypertension, a diuretic first!].
    MMW Fortschritte der Medizin, 2003, Jan-16, Volume: 145, Issue:1-2

    Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypert

2003
Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient.
    British journal of clinical practice. Supplement, 1994, Volume: 74

    Topics: Coronary Disease; Doxazosin; Humans; Hypertension; Hypertrophy, Left Ventricular; Insulin Resistance

1994
Doxazosin dropped from ALLHAT study.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2000, Apr-15, Volume: 57, Issue:8

    Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Clinical Trials as Topic; Coronary Disease; D

2000
Discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack.
    Lancet (London, England), 2000, Apr-29, Volume: 355, Issue:9214

    Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Heart Failure; Humans

2000
How effective is doxazosin compared with chlorthalidone in the treatment of hypertension?
    The Journal of family practice, 2000, Volume: 49, Issue:7

    Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Coronary Disease; Diuretics;

2000
Doxazosin arm of the ALLHAT study discontinued: how equal are antihypertensive drugs? Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial.
    Current hypertension reports, 2000, Volume: 2, Issue:3

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors;

2000
[Are all antihypertensive agents equal? Cardiovascular events in hypertensive patients randomized to treatment with doxazosin or chlorthalidone. The ALLHAT study].
    Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology, 2000, Volume: 1, Issue:9

    Topics: Adrenergic alpha-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive

2000
Transmural heterogeneity of postjunctional alpha 2 adrenergic coronary vasoconstriction in hypoperfused cat left ventricle.
    Cardiovascular research, 1992, Volume: 26, Issue:3

    Topics: Adrenergic alpha-Antagonists; Animals; Benzazepines; Cats; Coronary Disease; Coronary Vessels; Doxaz

1992
Management of coronary heart disease risk factors in hypertensive patients: clinical experience with doxazosin. A symposium. London, England, January 26, 1990. Proceedings.
    American heart journal, 1991, Volume: 121, Issue:1 Pt 2

    Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Humans; Hypertension; Prazosin; Risk Factors

1991
Blood flow regulation during acute regional ischemia in feline hearts: importance of postjunctional alpha 1- and alpha 2-adrenoceptors.
    Journal of cardiovascular pharmacology, 1991, Volume: 18, Issue:4

    Topics: Adrenergic alpha-Antagonists; Animals; Benzazepines; Catecholamines; Cats; Coronary Circulation; Cor

1991
Regional perfusion in hearts with acute coronary artery occlusion and subsequent beta 2- and alpha 1-adrenergic blockade.
    Clinical physiology (Oxford, England), 1990, Volume: 10, Issue:2

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Cats; Coronary Circulation; Coro

1990
Hypertension, coronary risk and alpha-blockade.
    Journal of human hypertension, 1990, Volume: 4 Suppl 3

    Topics: Adrenergic alpha-Antagonists; Coronary Disease; Doxazosin; Humans; Hypertension; Prazosin; Risk Fact

1990
Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.
    Journal of human hypertension, 1990, Volume: 4 Suppl 3

    Topics: Adrenergic alpha-Antagonists; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dox

1990
Does alpha 1-adrenergic blockade influence regional blood flow regulation in hearts with coronary artery occlusion?
    Clinical physiology (Oxford, England), 1989, Volume: 9, Issue:2

    Topics: Animals; Atenolol; Cats; Coronary Circulation; Coronary Disease; Doxazosin; Female; Male; Prazosin;

1989
Delayed recovery of homogeneous perfusion distribution in isolated rat heart after vasodilatation induced by alpha 1 adrenoceptor blockade during postischaemic reperfusion.
    Cardiovascular research, 1989, Volume: 23, Issue:11

    Topics: Animals; Blood Flow Velocity; Coronary Circulation; Coronary Disease; Doxazosin; L-Lactate Dehydroge

1989
Alpha-blockade for hypertension: indifferent past, uncertain future.
    Lancet (London, England), 1989, May-13, Volume: 1, Issue:8646

    Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Drug Evaluation; Humans; Hypertension; Prazosi

1989
[Reduction of coronary risk factors with selective alpha-blockers. International Doxazosin Symposium. Frankfurt/Main, 7 June 1986].
    Fortschritte der Medizin. Supplement : die Kongressinformation fur die Praxis, 1986, Volume: 8

    Topics: Adrenergic alpha-Antagonists; Coronary Disease; Doxazosin; Humans; Prazosin; Risk

1986
Doxazosin in the treatment of mild and moderate essential hypertension in general medical practice.
    American heart journal, 1988, Volume: 116, Issue:6 Pt 2

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease

1988
Clinical experience with doxazosin in general medical practice.
    American heart journal, 1988, Volume: 116, Issue:6 Pt 2

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease

1988
Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy.
    American heart journal, 1988, Volume: 116, Issue:6 Pt 2

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Coronary Disease; Doxazosin; Dru

1988
Doxazosin in the treatment of patients with mild or moderate hypertension and mild or moderate renal insufficiency.
    American heart journal, 1988, Volume: 116, Issue:6 Pt 2

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease

1988
A single-blind study of doxazosin in the treatment of mild-to-moderate essential hypertensive patients with concomitant noninsulin-dependent diabetes mellitus.
    American heart journal, 1988, Volume: 116, Issue:6 Pt 2

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease

1988
The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine.
    American heart journal, 1988, Volume: 116, Issue:6 Pt 2

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease

1988
A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy.
    American heart journal, 1988, Volume: 116, Issue:6 Pt 2

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensiv

1988
A symposium: Doxazosin: coronary artery disease risk factor management. June 7, 1986, Frankfurt, Germany.
    The American journal of cardiology, 1987, May-29, Volume: 59, Issue:14

    Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Humans; Hypertension; Prazosin; Risk

1987
Doxazosin: A distinctive approach to risk reduction of coronary heart disease in hypertensive patients. Proceedings of a symposium. Hamburg, West Germany, January 30, 1988.
    American heart journal, 1988, Volume: 116, Issue:6 Pt 2

    Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Humans; Hypertension; Prazosin; Risk Factors

1988